A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
The Pre-Approval Inspection (PAI) was completed on February 13, 2026, and the company is initiating corrective actions.
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
The initiative, delivered in collaboration with Accenture, integrates digitally enabled operating models powered by advanced analytics and AI across the company’s procurement, manufacturing, and distribution networks
The recommendation is based on new data from continuous safety monitoring of medicines in the EU
The trial, which compared Retevmo to placebo, met its primary endpoint with a “highly statistically significant and clinically meaningful improvement” in investigator-assessed EFS for patients with stage II–IIIA disease
The enhancements will improve environmental sustainability, strengthen material governance, and boost utility reliability
Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
